UA79435C2 - Method for preventing gel formation of teverelix, suspension of teverelix (variants), method for producing composition and suspension of teverelix - Google Patents
Method for preventing gel formation of teverelix, suspension of teverelix (variants), method for producing composition and suspension of teverelix Download PDFInfo
- Publication number
- UA79435C2 UA79435C2 UA2004031905A UA2004031905A UA79435C2 UA 79435 C2 UA79435 C2 UA 79435C2 UA 2004031905 A UA2004031905 A UA 2004031905A UA 2004031905 A UA2004031905 A UA 2004031905A UA 79435 C2 UA79435 C2 UA 79435C2
- Authority
- UA
- Ukraine
- Prior art keywords
- suspension
- teverelix
- peptide
- aqueous suspension
- isotonic agent
- Prior art date
Links
- 239000000725 suspension Substances 0.000 title claims abstract description 47
- 238000000034 method Methods 0.000 title claims abstract description 18
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 12
- 239000000203 mixture Substances 0.000 title claims description 16
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 title claims 11
- 108010070670 antarelix Proteins 0.000 title claims 8
- 229950011372 teverelix Drugs 0.000 title claims 8
- 238000004519 manufacturing process Methods 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 28
- 239000007900 aqueous suspension Substances 0.000 claims abstract description 18
- 238000002156 mixing Methods 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims description 15
- 239000007951 isotonicity adjuster Substances 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000012736 aqueous medium Substances 0.000 claims description 6
- 239000013081 microcrystal Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 3
- 230000003111 delayed effect Effects 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 6
- 239000012530 fluid Substances 0.000 abstract description 3
- 239000005557 antagonist Substances 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 241000289669 Erinaceus europaeus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- -1 acetate Chemical class 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31761601P | 2001-09-06 | 2001-09-06 | |
| PCT/EP2002/009537 WO2003022243A2 (en) | 2001-09-06 | 2002-08-27 | Sustained release of microcrystalline peptide suspensions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA79435C2 true UA79435C2 (en) | 2007-06-25 |
Family
ID=23234486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2004031905A UA79435C2 (en) | 2001-09-06 | 2002-08-27 | Method for preventing gel formation of teverelix, suspension of teverelix (variants), method for producing composition and suspension of teverelix |
Country Status (27)
| Country | Link |
|---|---|
| US (5) | US7098305B2 (ja) |
| EP (2) | EP1423150B1 (ja) |
| JP (3) | JP2005504787A (ja) |
| KR (2) | KR100818904B1 (ja) |
| CN (1) | CN100386116C (ja) |
| AR (1) | AR042592A1 (ja) |
| AT (1) | ATE463258T1 (ja) |
| AU (1) | AU2002337025B2 (ja) |
| BR (1) | BR0212333A (ja) |
| CA (1) | CA2459309C (ja) |
| CY (1) | CY1118642T1 (ja) |
| DE (1) | DE60235896D1 (ja) |
| DK (1) | DK2198888T3 (ja) |
| ES (2) | ES2362505T3 (ja) |
| HK (1) | HK1062148A1 (ja) |
| HU (1) | HUP0402099A2 (ja) |
| IL (1) | IL160443A0 (ja) |
| MX (1) | MXPA04002185A (ja) |
| NO (1) | NO20040938L (ja) |
| NZ (1) | NZ531734A (ja) |
| PL (1) | PL368056A1 (ja) |
| PT (1) | PT2198888T (ja) |
| RU (1) | RU2311195C2 (ja) |
| TW (1) | TWI249409B (ja) |
| UA (1) | UA79435C2 (ja) |
| WO (1) | WO2003022243A2 (ja) |
| ZA (1) | ZA200401390B (ja) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
| US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| US7658938B2 (en) * | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| US7358330B2 (en) * | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
| US7098305B2 (en) | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
| WO2004010957A2 (en) * | 2002-07-31 | 2004-02-05 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| AR044852A1 (es) * | 2003-06-24 | 2005-10-05 | Novartis Ag | Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina |
| GB0320806D0 (en) | 2003-09-05 | 2003-10-08 | Astrazeneca Ab | Therapeutic treatment |
| BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
| GB0428151D0 (en) * | 2004-12-22 | 2005-01-26 | Novartis Ag | Organic compounds |
| EP1674082A1 (de) * | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
| GB0511269D0 (en) * | 2005-06-02 | 2005-07-13 | Creative Peptides Sweden Ab | Sustained release preparation of pro-insulin C-peptide |
| WO2007084460A2 (en) * | 2006-01-18 | 2007-07-26 | Qps, Llc | Pharmaceutical compositions with enhanced stability |
| US7704977B2 (en) * | 2006-04-07 | 2010-04-27 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| WO2008071984A1 (en) * | 2006-12-13 | 2008-06-19 | Ardana Bioscience Limited | Administration of the gonadotropin-releasing hormone antagonist teverelix |
| ES2381788T3 (es) | 2007-07-16 | 2012-05-31 | Genentech, Inc. | Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso |
| WO2009012256A1 (en) | 2007-07-16 | 2009-01-22 | Genentech, Inc. | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
| IL287292B (en) | 2008-01-31 | 2022-09-01 | Genentech Inc | and fusion antibody-drug-cd79b engineered antibodies cysteine- |
| WO2009137078A1 (en) * | 2008-05-07 | 2009-11-12 | Merrion Research Iii Limited | Compositions of peptides and processes of preparation thereof |
| US20100215743A1 (en) * | 2009-02-25 | 2010-08-26 | Leonard Thomas W | Composition and drug delivery of bisphosphonates |
| EP2424503B1 (en) * | 2009-05-01 | 2017-07-05 | Ferring BV | Composition for the treatment of prostate cancer |
| CN102711728B (zh) | 2010-01-13 | 2016-01-20 | 益普生制药股份有限公司 | 用于延缓释放生长抑素类似物的药物组合物的制备方法 |
| US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| US9089484B2 (en) * | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
| EP2600887A4 (en) * | 2010-07-09 | 2014-01-22 | Amylin Pharmaceuticals Llc | MICROCRYSTALLINE AGONISTS OF Y-RECEPTORS |
| KR20140026354A (ko) | 2011-01-07 | 2014-03-05 | 메리온 리서치 Ⅲ 리미티드 | 경구 투여용 철의 제약 조성물 |
| AU2012395148B2 (en) | 2012-11-24 | 2016-10-27 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| EP2823808A1 (en) | 2013-07-09 | 2015-01-14 | Ipsen Pharma S.A.S. | Pharmaceutical composition for a sustained release of lanreotide |
| EP2832361A1 (en) * | 2013-07-29 | 2015-02-04 | Ipsen Pharma S.A.S. | Aqueous sustained release compositions of LHRH analogs |
| CN104844694A (zh) * | 2014-02-17 | 2015-08-19 | 深圳翰宇药业股份有限公司 | 一种醋酸加尼瑞克的制备方法 |
| WO2015127685A1 (en) | 2014-02-28 | 2015-09-03 | Hangzhou Dac Biotech Co., Ltd | Charged linkers and their uses for conjugation |
| EP3689910A3 (en) | 2014-09-23 | 2020-12-02 | F. Hoffmann-La Roche AG | Method of using anti-cd79b immunoconjugates |
| JP7211704B2 (ja) | 2015-01-29 | 2023-01-24 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤 |
| CA2991973C (en) | 2015-07-12 | 2021-12-07 | Suzhou M-Conj Biotech Co., Ltd. | Bridge linkers for conjugation of a cell-binding molecule |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| KR102459469B1 (ko) | 2016-11-14 | 2022-10-26 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
| AU2018212806A1 (en) * | 2017-01-30 | 2019-07-18 | Antev Limited | A composition comprising at least one GnRH antagonist |
| JP2020525528A (ja) | 2017-06-30 | 2020-08-27 | アンテブ リミテッド | 急性尿閉を治療するための組成物を含むシリンジ |
| EP3560555A1 (en) * | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
| MA52794A (fr) * | 2018-05-28 | 2021-04-14 | Jiangyin Usun Pharmaceutical Co Ltd | Nouvelle utilisation pharmaceutique |
| EP3590525A1 (en) * | 2018-07-05 | 2020-01-08 | Antev Limited | Teverelix-tfa composition |
| EP3590524B1 (en) * | 2018-07-05 | 2020-11-04 | Antev Limited | A method of reconstituting a teverelix-tfa composition |
| EP3590526A1 (en) * | 2018-07-05 | 2020-01-08 | Antev Limited | A lyophilization process and a teverelix-tfa lyophilizate obtained thereby |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2668866A (en) * | 1951-08-14 | 1954-02-09 | Shell Dev | Isomerization of paraffin wax |
| GB1245187A (en) | 1969-02-14 | 1971-09-08 | Continental Can Co | Hot melt adhesive composition |
| JPS5242506A (en) | 1975-10-02 | 1977-04-02 | Toa Nenryo Kogyo Kk | Hydrotreating process of petroleum wax |
| JPS5335705A (en) * | 1976-09-14 | 1978-04-03 | Toa Nenryo Kogyo Kk | Hydrogenation and purification of petroleum wax |
| US4186078A (en) * | 1977-09-12 | 1980-01-29 | Toa Nenryo Kogyo Kabushiki Kaisha | Catalyst and process for hydrofining petroleum wax |
| US4239546A (en) * | 1978-07-21 | 1980-12-16 | Petrolite Corporation | Hydrocarbon polymers to improve the hardness of waxes |
| US4256737A (en) | 1979-06-11 | 1981-03-17 | Syntex (U.S.A.) Inc. | Long acting depot injectable formulations for LH-RH analogues |
| US4266737A (en) * | 1979-11-05 | 1981-05-12 | Arrow Converting Equipment, Inc. | Air differential mandrel and method of differentially winding and rewinding tapes |
| US4415649A (en) * | 1981-02-25 | 1983-11-15 | E. I. Du Pont De Nemours & Co. | Flexographic printing plates containing blended adhesives |
| US4839422A (en) * | 1987-12-23 | 1989-06-13 | Exxon Chemical Patents Inc. | Ternary adhesive compositions |
| US5110904A (en) * | 1989-08-07 | 1992-05-05 | Abbott Laboratories | Lhrh analogs |
| DE68928278T2 (de) | 1988-02-10 | 1998-03-12 | Tap Pharmaceuticals Inc | Lhrh-analog |
| JP2672677B2 (ja) | 1989-02-09 | 1997-11-05 | タツプ・フアーマシユーテイカルズ・インコーポレイテツド | Ｌｈｒｈ同族体 |
| EP0593491B1 (en) * | 1991-04-25 | 1996-10-23 | DEGHENGHI, Romano | Luteinizing hormone releasing hormone antagonist peptides |
| ES2127835T3 (es) * | 1992-10-26 | 1999-05-01 | Sanol Arznei Schwarz Gmbh | Procedimiento para la preparacion de microcapsulas. |
| EP0673254A4 (en) | 1992-12-04 | 1998-11-18 | Abbott Lab | HORMONE ANTAGONISTS RELEASING LUTEINIZING HORMONE (LHRH) OF MODIFIED DECAPEPTIDES IN POSITION 6. |
| JP3568952B2 (ja) | 1992-12-18 | 2004-09-22 | アボット・ラボラトリーズ | ５位及び６位に修飾アミノアシル残基を有するｌｈｒｈ拮抗薬 |
| CA2178592C (en) | 1993-12-09 | 2009-07-28 | Jurgen Engel | Long-acting injection suspensions and a process for their preparation |
| DE4342092B4 (de) * | 1993-12-09 | 2007-01-11 | Zentaris Gmbh | Langwirkende Injektionssuspension und Verfahren zur Herstellung |
| JP3101695B2 (ja) | 1996-07-24 | 2000-10-23 | 日本航空電子工業株式会社 | 軟ｘ線光学素子用多層膜 |
| US5968895A (en) * | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| DE19813849A1 (de) * | 1998-03-27 | 1999-09-30 | Degussa | Verfahren zur einstufigen Umsalzung und Aufreinigung von Oligopeptiden |
| CO5160256A1 (es) | 1999-02-08 | 2002-05-30 | Zentaris Ag | Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion |
| DE10040700A1 (de) * | 2000-08-17 | 2002-02-28 | Asta Medica Ag | Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung |
| US7098305B2 (en) * | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
| JP4505750B2 (ja) | 2006-01-27 | 2010-07-21 | 東海ゴム工業株式会社 | 制振装置 |
-
2002
- 2002-02-19 US US10/080,130 patent/US7098305B2/en not_active Expired - Lifetime
- 2002-08-27 UA UA2004031905A patent/UA79435C2/uk unknown
- 2002-08-27 ES ES02772214T patent/ES2362505T3/es not_active Expired - Lifetime
- 2002-08-27 CA CA2459309A patent/CA2459309C/en not_active Expired - Lifetime
- 2002-08-27 DE DE60235896T patent/DE60235896D1/de not_active Expired - Lifetime
- 2002-08-27 KR KR1020047003371A patent/KR100818904B1/ko active IP Right Grant
- 2002-08-27 BR BR0212333-9A patent/BR0212333A/pt not_active IP Right Cessation
- 2002-08-27 CN CNB028173775A patent/CN100386116C/zh not_active Expired - Lifetime
- 2002-08-27 AU AU2002337025A patent/AU2002337025B2/en not_active Ceased
- 2002-08-27 NZ NZ531734A patent/NZ531734A/en not_active IP Right Cessation
- 2002-08-27 WO PCT/EP2002/009537 patent/WO2003022243A2/en active Application Filing
- 2002-08-27 AT AT02772214T patent/ATE463258T1/de active
- 2002-08-27 PL PL02368056A patent/PL368056A1/xx unknown
- 2002-08-27 MX MXPA04002185A patent/MXPA04002185A/es not_active Application Discontinuation
- 2002-08-27 IL IL16044302A patent/IL160443A0/xx unknown
- 2002-08-27 KR KR1020077021972A patent/KR20070107161A/ko not_active Application Discontinuation
- 2002-08-27 HU HU0402099A patent/HUP0402099A2/hu unknown
- 2002-08-27 PT PT100030469T patent/PT2198888T/pt unknown
- 2002-08-27 ES ES10003046.9T patent/ES2618777T3/es not_active Expired - Lifetime
- 2002-08-27 RU RU2004110615/15A patent/RU2311195C2/ru not_active IP Right Cessation
- 2002-08-27 EP EP02772214A patent/EP1423150B1/en not_active Expired - Lifetime
- 2002-08-27 DK DK10003046.9T patent/DK2198888T3/en active
- 2002-08-27 EP EP10003046.9A patent/EP2198888B1/en not_active Expired - Lifetime
- 2002-08-27 JP JP2003526373A patent/JP2005504787A/ja active Pending
- 2002-08-29 TW TW091119713A patent/TWI249409B/zh not_active IP Right Cessation
- 2002-09-05 AR ARP020103358A patent/AR042592A1/es unknown
-
2004
- 2004-02-20 ZA ZA200401390A patent/ZA200401390B/en unknown
- 2004-03-04 NO NO20040938A patent/NO20040938L/no not_active Application Discontinuation
- 2004-07-15 HK HK04105185.0A patent/HK1062148A1/xx not_active IP Right Cessation
-
2006
- 2006-06-12 US US11/450,293 patent/US20060228385A1/en not_active Abandoned
- 2006-06-12 US US11/450,292 patent/US20060229238A1/en not_active Abandoned
-
2010
- 2010-01-28 JP JP2010016716A patent/JP5757686B2/ja not_active Expired - Lifetime
- 2010-06-07 US US12/795,246 patent/US20100239683A1/en not_active Abandoned
-
2011
- 2011-09-01 US US13/224,105 patent/US8415300B2/en not_active Expired - Lifetime
-
2013
- 2013-06-10 JP JP2013122235A patent/JP2013177449A/ja active Pending
-
2017
- 2017-02-02 CY CY20171100156T patent/CY1118642T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA79435C2 (en) | Method for preventing gel formation of teverelix, suspension of teverelix (variants), method for producing composition and suspension of teverelix | |
| AU2002337025A1 (en) | Sustained release of microcrystalline peptide suspensions | |
| US5916582A (en) | Aqueous formulations of peptides | |
| ES2541908T3 (es) | Microesferas biodegradables de liberación prolongada y su procedimiento de preparación | |
| NZ333580A (en) | Non-Aqueous protic peptide formulations, preferably LHRH | |
| ES2338217T3 (es) | Antagonistas de la hormona liberadora de gonadotrpina en concentraciones formadoras de gel. | |
| PT99236B (pt) | Processo para a preparacao de um polimero compreendendo um acido polilactico, um copolimero de acido glicolico e um acido carboxilico para utilizacao numa composicao de libertacao prolongada e de composicoes que o contem | |
| RU2333743C2 (ru) | Фармацевтическая гелевая композиция для лечения заболеваний, способ ее получения и соответствующий набор | |
| ES2261671T3 (es) | Mezcla farmaceutica que incluye una estaurosporina poco soluble en agua, un surfactante y un polimero soluble en agua. | |
| BG63621B1 (bg) | Стабилизирани фармацевтични състави на база хинупристин и далфопристин и тяхното получаване | |
| AU2004242540B2 (en) | Aqueous formulations of peptides | |
| KR20000022449A (ko) | 펩티드의 수성 제제 | |
| CN1698616A (zh) | 双嘧达莫环糊精及环糊精衍生物的包合物及其制备方法 |